Back to 13F data
Q1 2026
ALNYLAM PHARMACEUTICALS INC
Original CUSIPs: 02043Q107. This page shows current managers, quarterly changes, and primary SEC sources.
Current managers
1
Combined value
$35.3M
Current managers
1
Calculated from each manager’s latest available 13F.
Total shares
106,592
Aggregated at company level with original CUSIP details preserved.
Combined value
$35.3M
Market values are added across managers reporting the same quarter.
Themes
Unclassified
Local mappings are used only for search and classification.
Four-quarter trend
Four-quarter ownership trend
Manager actions by quarter
Current tracked managers holding this company
| Manager | Quarter | Market value | Shares | Portfolio weight | Current-quarter change | Share change | Value change | SEC source |
|---|---|---|---|---|---|---|---|---|
| Bridgewater Associates Ray Dalio / Bridgewater | Q1 2026 | $35,268,095 | 106,592 | 0.16% | Increased +24.50% | +20,975 | +$1,222,495 | XML 05/15/2026 |
Original CUSIP details
| Manager | Issuer | CUSIP | Security class | Market value | Shares | Weight | Source |
|---|---|---|---|---|---|---|---|
| Bridgewater Associates | ALNYLAM PHARMACEUTICALS INC | 02043Q107 | COM | $35,268,095 | 106,592 | 0.16% | SEC XML |
Quarterly holdings details
| Quarter | Current managers | Combined value | Total shares | Manager details |
|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0 | |
| Q3 2025 | 1 | $15,463,416 | 33,911 | Bridgewater Associates New position |
| Q4 2025 | 1 | $34,045,600 | 85,617 | Bridgewater Associates Increased |
| Q1 2026 | 1 | $35,268,095 | 106,592 | Bridgewater Associates Increased |
Data source
Holdings facts come from SEC 13F information tables. Tickers, company aliases, and themes are used only for search and normalized display, not as a holdings source.